Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Current Deferred Revenue (2016 - 2025)

Sonoma Pharmaceuticals has reported Current Deferred Revenue over the past 15 years, most recently at $314000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 3.97% year-over-year to $314000.0; the TTM value through Dec 2025 reached $314000.0, up 3.97%, while the annual FY2025 figure was $641000.0, 321.71% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $314000.0 at Sonoma Pharmaceuticals, down from $750000.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $1.2 million in Q1 2022 and troughed at $75000.0 in Q4 2023.
  • A 5-year average of $313600.0 and a median of $192000.0 in 2021 define the central range for Current Deferred Revenue.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 358.05% in 2022 and later tumbled 83.73% in 2023.
  • Year by year, Current Deferred Revenue stood at $100000.0 in 2021, then changed by 0.0% to $100000.0 in 2022, then dropped by 25.0% to $75000.0 in 2023, then skyrocketed by 302.67% to $302000.0 in 2024, then grew by 3.97% to $314000.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for SNOA at $314000.0 in Q4 2025, $750000.0 in Q3 2025, and $731000.0 in Q2 2025.